Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT06251063
Other study ID # IRB-P00047080
Secondary ID
Status Recruiting
Phase N/A
First received
Last updated
Start date April 1, 2024
Est. completion date May 1, 2025

Study information

Verified date April 2024
Source Boston Children's Hospital
Contact Grace Y Wang
Phone 617-919-6212
Email grace.wang@childrens.harvard.edu
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

The goal of this study is to test a web-based psychoeducational resource for adolescents with central disorders of hypersomnolence and their families. The investigators hope to assess the website's usability, acceptability, and feasibility, as well as its potential effect on social relationship health. Participants will be asked to review the content of the psychoeducational websites. The participants will then provide feedback on the website, as well as the adolescent's social relationships and social health before and after reviewing the website through online surveys.


Description:

The American Academy of Sleep Medicine's clinical practice guideline task force concluded that "reliance on medications alone to treat CNS hypersomnia conditions is likely insufficient." Our stakeholder data demonstrated that this issue is a significant challenge in the domain of social relationship health for children with narcolepsy type 1 and 2 (NT1/NT2) and idiopathic hypersomnia (IH). With one peak for symptom onset in adolescence, a critical period in a child's social development, children with NT1/NT2/IH and their families report significant social sequelae of the disorder and its treatment that have lifelong implications. To address this important, yet consistently overlooked real-life concern for adolescents with CDH, the investigators intend to assess an online psychoeducational website that the investigators designed to provide families with the knowledge and resources to improve the adolescent's social relationship health. A total of 45 families will participate in a single-arm usability, feasibility, and acceptability trial. Eligible families will be provided with instructions on how to access the website. Participants will be encouraged to return to the website as often as needed to review content. For the purposes of this study, participants will be instructed to review all intervention materials within one month of receiving website access. The participants will then complete feedback questionnaires on the secure online platform REDCap. This study will inform a future randomized controlled trial testing the efficacy of the investigators' intervention. The investigators' stakeholder informed program will be the first of its kind for children with NT1/NT2/IH, with the potential to be widely disseminated.


Recruitment information / eligibility

Status Recruiting
Enrollment 45
Est. completion date May 1, 2025
Est. primary completion date April 1, 2025
Accepts healthy volunteers No
Gender All
Age group 10 Years to 17 Years
Eligibility Inclusion Criteria: - Adolescent from 10-17 years of age and parent of the adolescent - Adolescent has physician-diagnosed narcolepsy type 1 or type 2, or idiopathic hypersomnia - English fluency - Interest in learning more about how to improve social health for adolescents with a CDH

Study Design


Related Conditions & MeSH terms


Intervention

Behavioral:
Web-based psychoeducational resource
The website will incorporate animations/illustrations to enhance comprehension, patient stories, and video-based expert explanations. The materials will address the following content areas: Provide families with data demonstrating how prevalent social relationship struggles are for children with CDH. Describe specific social challenges that commonly affect children with CDH. Explain the impact that medications typically prescribed for CDH may have on social relationship health. Help families advocate for their child's social needs at school. Support children and their families in decision-making about appropriate disclosure with peers at school and in extracurricular settings. Offer strategies to support families in raising the issue of social relationship health with the child's sleep physician. Provide a list of programming which offers children both structured and unstructured opportunities for social engagement

Locations

Country Name City State
United States Boston Children's Hospital Boston Massachusetts

Sponsors (2)

Lead Sponsor Collaborator
Boston Children's Hospital American Academy of Sleep Medicine

Country where clinical trial is conducted

United States, 

References & Publications (1)

Zhou ES, Revette A, Heckler GK, Worhach J, Maski K, Owens JA. Building a deeper understanding of social relationship health in adolescents with narcolepsy disorder. J Clin Sleep Med. 2023 Mar 1;19(3):491-498. doi: 10.5664/jcsm.10372. — View Citation

Outcome

Type Measure Description Time frame Safety issue
Primary Usability System Usability Scale. The minimum score is 10 and the maximum score is 50. Each question is measured on a scale from 1-5. A higher score indicates higher usability (better outcome). Completed by both the parent and child. 5 weeks
Primary Acceptability (Enrollment) Proportion of eligible families who express interest in the study choosing to enroll. 5 weeks
Primary Acceptability (Satisfaction) Satisfaction subscale of the Usability, Satisfaction, and Ease of use scale. Each question is measured on a scale from 1-7. The minimum score is 7 and the maximum score is 49. A higher score indicates higher website satisfaction (better outcome). 5 weeks
Primary Acceptability (Recommend Website) Proportion of participants who respond positively to the Post-Intervention questionnaire item "Would you recommend this website to other families of children with NT1/NT2/IH?". 5 weeks
Primary Feasibility (Website Access) Proportion of participants that access the website at least once during the study period. 5 weeks
Primary Feasibility (Assessment Completion) Proportion of participants who complete the Post-Intervention Assessment. 5 weeks
Secondary Relationship Quality Patient Reported Outcomes Measurement Information System Pediatric Peer Relationships Scale (PROMIS-PPRS). Each question is measured on a scale of 0-4. The minimum score is 0 and the maximum score is 32. A higher score means better peer relationships (better outcome). 0 weeks and 5 weeks
Secondary Social Problems (Loneliness) UCLA Three-Item Loneliness Scale. Completed by patient and parent. Each question is measured on a scale of 1-3. The minimum score is 3 and the maximum score is 9. A higher score means more loneliness (worse outcome). 0 weeks and 5 weeks
Secondary Social Problems (Social Relationships) NIH Toolbox Pediatric Social Relationship Scales. Using the Emotional Support, Friendship, and Perceived Rejection Items. Each question is measured on a scale of 1-5. The minimum score is 19 and the maximum score is 95. A higher score means better social relationships (better outcome). 0 weeks and 5 weeks
See also
  Status Clinical Trial Phase
Recruiting NCT04026958 - Clarithromycin Mechanisms in Hypersomnia Syndromes Phase 2
Completed NCT02512588 - A Study of Safety and Efficacy of BTD-001 in Treatment of Patients With Idiopathic Hypersomnia (IH) or Narcolepsy Type 2 Phase 2
Completed NCT01183312 - Flumazenil for the Treatment of Primary Hypersomnia Phase 1/Phase 2
Completed NCT03597555 - Sodium Oxybate in Idiopathic Hypersomnia Phase 2/Phase 3
Completed NCT03356938 - The Role of the Circadian System in Neurological Sleep-wake Disorders N/A
Completed NCT03533114 - A Multicenter Study of the Efficacy and Safety of JZP-258 in the Treatment of Idiopathic Hypersomnia (IH) With an Open-label Safety Extension Phase 3
Active, not recruiting NCT03542851 - A Study of Oral BTD-001 in Adults With Idiopathic Hypersomnia Phase 2
Completed NCT05156047 - A Phase 3 Study to Assess the Safety and Efficacy of Pitolisant in Adult Patients With Idiopathic Hypersomnia Phase 3
Enrolling by invitation NCT05371483 - Cardiovascular and Cognitive Implications of Central Disorders of Hypersomnolence and Their Treatments
Not yet recruiting NCT06252571 - a Chronobiological Treatment Combining Evening Melatonin and Morning Light Therapy in Idiopathic Hypersomnia: a Prospective, Double Bind, Randomized, Placebo-controlled -Trial Phase 2
Completed NCT04827329 - Anesthetic Management of Patients With Chronic Sleep Disorders
Not yet recruiting NCT06457945 - Mind-wandering and Predictive Processes in Narcolepsy: a Putative Mechanism Through Covert REM Intrusions N/A
Recruiting NCT05875974 - Ph4 PSG Combined JZP258-407 Phase 4
Recruiting NCT01793168 - Rare Disease Patient Registry & Natural History Study - Coordination of Rare Diseases at Sanford
Completed NCT01146600 - Clarithromycin for the Treatment of Hypersomnia Phase 2
Recruiting NCT04330963 - International Swiss Primary Hypersomnolence and Narcolepsy Cohort Study
Completed NCT04091438 - A Study of a Single Intravenous Infusion Dose of TAK-925 in Participants With Idiopathic Hypersomnia Phase 1
Recruiting NCT05615584 - Spectrometry (MRM) Versus I 125 Radioimmunoassay (RIA) for Quantification of Orexin-A of Patients With Hypersomnolence N/A
Recruiting NCT05837091 - Low Sodium Oxybate in Patients With Idiopathic Hypersomnia Phase 4
Recruiting NCT05321355 - Mainz Register of Patients With Sleep Disorders